MARKET

CLDI

CLDI

Calidi Biotherapeutics Inc
AMEX
0.1095
+0.0095
+9.50%
Pre Market: 0.1079 -0.0016 -1.46% 06:21 07/28 EDT
OPEN
0.1002
PREV CLOSE
0.1000
HIGH
0.1189
LOW
0.0969
VOLUME
233.69K
TURNOVER
0
52 WEEK HIGH
10.92
52 WEEK LOW
0.0950
MARKET CAP
2.11M
P/E (TTM)
-0.0211
1D
5D
1M
3M
1Y
5Y
1D
Calidi Biotherapeutics Presents New Data On CLD-401 Program That It Expects To Enter Clinic In Q1 Of 2027 And In Situ T-Cell Engager Program, At 2026 AACR D3 Conference
Benzinga · 1d ago
Weekly Report: what happened at CLDI last week (0720-0724)?
Weekly Report · 1d ago
Upcoming Stock Splits This Week (July 27 to July 31) – Stay Invested
TipRanks · 1d ago
Calidi Announces Reverse Stock Split; Shares Tumble 15% In Premarket Trading
NASDAQ · 07/21 12:46
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 07/21 12:05
Why Crown Holdings Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Benzinga · 07/21 09:11
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 07/20 21:05
Weekly Report: what happened at CLDI last week (0713-0717)?
Weekly Report · 07/20 09:48
More
About CLDI
Calidi Biotherapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is developing proprietary allogeneic stem cell-based and enveloped virus platforms to potentiate and deliver oncolytic viruses (vaccinia virus and adenovirus) and, potentially, other molecules to cancer patients. It is focused on developing two proprietary stem cell-based platforms and one enveloped vaccinia virus platform designed to protect the oncolytic virus, whether natural or engineered, from neutralization by the patient’s immune defenses, allowing for greater infection of the tumor cells and leading to a potential improvement in the antitumor activity of oncolytic viruses over traditional naked oncolytic virus therapies. Its product candidates include the CLD-101 product for high grade glioma (HGG), CLD-101 product for Recurrent HGG, CLD-201 product for solid tumors, CLD-301 (AAA) for multiple indications and CLD-400 (RTNova) for certain lung cancer and metastatic solid tumors.

Webull offers Calidi Biotherapeutics Inc stock information, including AMEX: CLDI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLDI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CLDI stock methods without spending real money on the virtual paper trading platform.